Klin Farmakol Farm. 2018;32(3):26-33 | DOI: 10.36290/far.2018.020

Treating pain with the fixed combination of diclofenac and orphenadrine

Tomáš Vymazal11, Karel Urbánek2
1 Klinika anesteziologie, resuscitace a intenzivní medicíny 2. LF UK a FN Motol
2 Ústav farmakologie LF UP a FN Olomouc

The fixed combination of orphenadrine and diclofenac for injection is characterized by the advantageous combination of analgesicand central myorelaxation effects. Its pharmacokinetics allows simple dosing once to twice a day and can significantly simplifyperioperative management of good analgesia by eliminating the risks associated with the repeated preparation and administrationof other analgesics. In common clinical practice, it is also used for the treatment of acute exacerbation of low back pain or inthe post-operative pain management. It also has an good safety profile.

Keywords: diclofenac, orphenadrine, pharmacology, muscle spasm, postoperative analgesia, low back pain, complications

Published: November 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vymazal T, Urbánek K. Treating pain with the fixed combination of diclofenac and orphenadrine. Klin Farmakol Farm. 2018;32(3):26-33. doi: 10.36290/far.2018.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Altman R, Bosch B, Brune K, Patrignani P, Young C. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015; 75(8): 859-877. Go to original source... Go to PubMed...
    2. Sneader W. Drug Discovery: A History. John Wiley & Sons, London, 2005. Go to original source...
    3. Scholer DW, Ku EC, Boettcher I, Schweizer A. Pharmacology of diclofenac sodium. Am J Med. 1986; 80(4 B): 34-38. Go to original source...
    4. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010; 26(7): 1715-1731. Go to original source... Go to PubMed...
    5. The Oxford League Table of Analgesic Efficacy. [Online]. Dostupné na: http://www.medicine.ox.ac.uk.
    6. Syvälahti EK, Kunelius R, Laurén L. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988; 62(2): 90-94. Go to original source...
    7. Rumore MM, Schlichting DA. Analgesic effects of antihistaminics. Life Sci. 1985; 36(5): 403-416. Go to original source...
    8. Kornhuber J, Parsons CG, Hartmann S, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995; 102(3): 237-246. Go to original source...
    9. Desaphy JF, Dipalma A, De Bellis M, et al. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009; 142(3): 225-235. Go to original source...
    10. SPC Neodolpasse(R). Dostupné na www.sukl.cz.
    11. Hunskaar S, Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res. 1991; 19(2): 71-87. Go to original source...
    12. Schaffler K, Reitmeir P, Gschanes A, Eggenreich U. Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin. Drugs R D. 2005; 6(4): 189-199. Go to original source...
    13. Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol. 1983; 25(3): 389-394. Go to original source...
    14. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997; 33(3): 184-213. Go to original source... Go to PubMed...
    15. Ellison T, Snyder A, Bolger J, Okun R. Metabolism of orphenadrine citrate in man. J Pharmacol Exp Ther. 1971; 176(2): 284-295. Go to PubMed...
    16. Lee SY, Oh HJ, Kim JW, Kim YG, Moon CJ, Lee EH. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 839(1-2): 118-123. Go to original source...
    17. Neodolpasse: Clinical Expert Statement. Fresenius Kabi 2012. [Online]. Dostupné na www.researchgate.net.
    18. PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors. [Online]. Dostupné na www.ema.europa.eu.
    19. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086. Go to original source... Go to PubMed...
    20. Whittaker VB. The effect of orphenadrine citrate by injection in skeletal muscle spasm using an electromyographic examination technique. Br J Clin Pract. 1969 Mar; 23(3): 115-119. Go to original source... Go to PubMed...
    21. Masterson JH, White AE. Electromyographic Validation of Pain Relief: A Pilot Study in Orthopedic Patients. Amer J of Orthopedics. 1966; 2: 36-40.
    22. Valtonen EJ. A Controlled Clinical trial of Chlormezanone, Orphenadrine, Orphenadrine/Paracetamol and Placebo in the Treatment of painful Skeletal Muscle Spasm. Annals of Clinical Research. 1975; 7: 85-88.
    23. Hunskaar S, Donnell D. Clinical and Pharmacological Review of the Efficacy of Orphenadrine and Its Combination with Paracetamol in Painful Conditions. J of Int Med Res. 1991; 19: 71-87. Go to original source... Go to PubMed...
    24. Casale R, Glynn CHJ, Buonocore M. Reduction of Spastic Hypertonia in Patiens with Spinal Cord Injury: A Double-Blind Comparison of Intravenous Orphenadrine Citrate and Placebo. Arch Phys Med Rehabil. 1995; 76: 660-664. Go to original source...
    25. Winter L, Post A. Analgetik Combinations with Orphenadrine in Oral Post-Surgical Pain. J Int Med Res. 1979; 7: 240-243. Go to original source...
    26. Uitz E, Aglas F, Wurm A, Rainer F. Diclofenac/Orphenadrin-Infusionstherapie bei Patienten mit aktivierten Arthrosen. Wien Med Wochenschr. 1998; 7: 179-183.
    27. Aglas F, Fruhwald FM, Chlud K. Ergebnisse einer Anwendungsbeobachtung mit Diclofenac/Orphenadrin-Infusionen bei Patienten mit muskuloskelettalen Krankenheiten und Funktionsstoerungen. Acta Med Austriaca. 1998; 25: 86-90. Go to PubMed...
    28. Bakris GL, Mulopulos GP, Tiwari S, Franclin C. Orphenadrine Citrate. Illinois Med Journal. 1982; 2: 106-108.
    29. Richards BL, Whittle SL, Buchbinder R. Musile relaxans for pain management in rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2012; 1: CD008922. Go to original source... Go to PubMed...
    30. Gombotz H, Lochner R, Sigl R, et al. Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical study. Wien Med Wochenschr. 2010; 160/19-20: 526-534. Go to original source... Go to PubMed...
    31. Tervo T, Petaja L, Lepisto P. A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago. Br J Clin Pract. 1976; 30(3): 62-64. Go to original source... Go to PubMed...
    32. Hakl M. Léčba bolestí zad. Čas Lék čes. 2018; 157: 62-66.
    33. Adamová B. Bolesti páteře. In: Hakl M a kol. Léčba bolesti. Praha: Mladá fronta, 2013: 170-182.
    34. Collaku A, Yue Y, Reed K. Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study. J Pain Res. 2017; 10: 669-678. Go to original source... Go to PubMed...
    35. Bojanovsky J, Chloupkova K. Comparative therapeutic effects of Meprobamate and Guaiacuran in anxiety neuroses. Act Nerv Super. 1962; 4: 232-233.
    36. See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008; 28: 207-213. Go to original source... Go to PubMed...
    37. MedlinePlus [Online]. U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 [cit. 25. 5. 2018]. Dostupné z: https://medlineplus.gov/druginfo/meds/a682162.html
    38. Malizia E, Sarcinelli L, Pascarella M, et al. Cardiotoxicity from Orphenadrine Intoxications in Humans. Arch Toxicol Suppl. 1980; (4): 425-427. Go to original source...
    39. Gilman AG, Rall TW, Nies AS. The Pharmacological Basis of Therapeutics. 10th Ed; Mc Graw Hill: 2001.
    40. Sanyuktha S, Sharath K, Biju T, Nitin S, Arvind S, Devanand S. NSAIDs and Bleeding in Periodontal Surgery Journal of Clinical and Diagnostic Research. 2014; 8(5): ZC17-ZC20. Go to PubMed...
    41. Bowen B, Yuan Y, James C, Rashid F. Short-Term Use of High-Dose Ibuprofen Linked to GI Bleeding. Clin Gastroenterol Hepatol. 2005; 3: 1-5. Go to original source...
    42. Mc Intyre BA, Philip RB, Inwood MJ. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Therap. 1978; 245: 616-621. Go to original source... Go to PubMed...
    43. Winkler SH, Barta S, Kehl V, Schröter C, Wagner F, Grifka J, Springorum HR, Craiovan B. Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial. Curr Med Res Opin. 2016; 32(1): 37-47. Go to original source... Go to PubMed...
    44. Ragavan J, Zheong U, Majakal V. Post-op pain and blood loss in total knee arthroplasty: an RCT using periarticular injection with diclofenac-based multimodal drugs. J Med Assoc Thai. 2014; 97(12): 1332-1337. Go to PubMed...
    45. Gupta A, Jakobsson J. Acetaminophen, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective inhibitors: an update. Plast Reconstr Surg. 2014; 134(4 Suppl 2): 24S-31S. Go to original source... Go to PubMed...
    46. Vymazal T, Beroušek J. Neodolpasse v časném pooperačním období neovlivňuje tvorbu krevního koagula - prospektivní kohortové sledování. Klin Farmakol Farm. 2017; 31(1): 10-12. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.